132 related articles for article (PubMed ID: 35818742)
1. Adverse analytical finding due to red blood cells transfusion: A rare case involving the diuretic dorzolamide.
Kintz P; Gheddar L; Raul JS
Drug Test Anal; 2022 Oct; 14(10):1785-1790. PubMed ID: 35818742
[TBL] [Abstract][Full Text] [Related]
2. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination.
Helmlin HJ; Mürner A; Steiner S; Kamber M; Weber C; Geyer H; Guddat S; Schänzer W; Thevis M
Forensic Sci Int; 2016 Oct; 267():166-172. PubMed ID: 27611956
[TBL] [Abstract][Full Text] [Related]
3. Cases reports: Unintended anti-doping rule violation after dorzolamide use several months prior to a doping control.
Pokrywka A; Skrzypiec-Spring M; Krzywański J; Rynkowski M; Saugy M; Faiss R
Drug Test Anal; 2021 Oct; 13(10):1803-1806. PubMed ID: 34463045
[TBL] [Abstract][Full Text] [Related]
4. Multiple incidence of the prescription diuretic hydrochlorothiazide in compounded nutritional supplements.
Favretto D; Visentin S; Scrivano S; Roselli E; Mattiazzi F; Pertile R; Vogliardi S; Tucci M; Montisci M
Drug Test Anal; 2019 Mar; 11(3):512-522. PubMed ID: 30194914
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a fast ultra-high-performance liquid chromatography tandem mass spectrometry method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair.
Lo Faro AF; Tini A; Gottardi M; Pirani F; Sirignano A; Giorgetti R; Busardò FP
Drug Test Anal; 2021 Aug; 13(8):1552-1560. PubMed ID: 33908166
[TBL] [Abstract][Full Text] [Related]
6. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
Kadam RS; Jadhav G; Ogidigben M; Kompella UB
Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
[TBL] [Abstract][Full Text] [Related]
7. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
Maren TH; Conroy CW; Wynns GC; Levy NS
J Ocul Pharmacol Ther; 1997 Feb; 13(1):23-30. PubMed ID: 9029437
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Sugrue MF
Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of dorzolamide.
Martens-Lobenhoffer J; Banditt P
Clin Pharmacokinet; 2002; 41(3):197-205. PubMed ID: 11929320
[TBL] [Abstract][Full Text] [Related]
10. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
[TBL] [Abstract][Full Text] [Related]
11. Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing.
Thevis M; Geyer H; Thomas A; Tretzel L; Bailloux I; Buisson C; Lasne F; Schaefer MS; Kienbaum P; Mueller-Stoever I; Schänzer W
J Pharm Biomed Anal; 2015 Nov; 115():208-13. PubMed ID: 26226108
[TBL] [Abstract][Full Text] [Related]
12. Analytical progresses of the World Anti-Doping Agency Olympic laboratories: a 2016 update from London to Rio.
Athanasiadou I; Voss S; Lyris E; Aljaber A; Alsayrafi M; Georgakopoulos C
Bioanalysis; 2016 Nov; 8(21):2265-2279. PubMed ID: 27665839
[TBL] [Abstract][Full Text] [Related]
13. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.
Ponticello GS; Sugrue MF; Plazonnet B; Durand-Cavagna G
Pharm Biotechnol; 1998; 11():555-74. PubMed ID: 9760696
[TBL] [Abstract][Full Text] [Related]
14. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide.
Biollaz J; Munafo A; Buclin T; Gervasoni JP; Magnin JL; Jaquet F; Brunner-Ferber F
Eur J Clin Pharmacol; 1995; 47(5):455-60. PubMed ID: 7720769
[TBL] [Abstract][Full Text] [Related]
15. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use.
Mareck U; Fusshöller G; Geyer H; Huestis MA; Scheiff AB; Thevis M
Drug Test Anal; 2021 Mar; 13(3):539-549. PubMed ID: 33125823
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction.
Wong BK; Bruhin PJ; Barrish A; Lin JH
Drug Metab Dispos; 1996 Jun; 24(6):659-63. PubMed ID: 8781782
[TBL] [Abstract][Full Text] [Related]
17. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Gugleta K
Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
[TBL] [Abstract][Full Text] [Related]
18. Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry.
Constanzer ML; Chavez CM; Matuszewski BK
J Pharm Biomed Anal; 1997 Apr; 15(7):1001-8. PubMed ID: 9160268
[TBL] [Abstract][Full Text] [Related]
19. The forensic response after an adverse analytical finding (doping) involving a selective androgen receptor modulator (SARM) in human athlete.
Kintz P
J Pharm Biomed Anal; 2022 Jan; 207():114433. PubMed ID: 34715583
[TBL] [Abstract][Full Text] [Related]
20. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
Heijl A; Strahlman E; Sverrisson T; Brinchman-Hansen O; Puustjärvi T; Tipping R
Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
